Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.63 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.43 |
| ▸ | CCKAR | P32238 | 5/20 | 0.41 |
| ▸ | CCKBR | P32239 | 5/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558792 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL1759114 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL4561886 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL4541595 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL4535900 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL15633597 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL2181197 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL4539094 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL4543138 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL4540624 | 1.00 | GLP1R (0.63) | GLP1RNOD1CCKARCCKBRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2068910-A2 | USE OF EXENDINS AND EXENDIN AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR ALTERING LIPOPROTEIN PARTICLE SIZE AND SUBCLASS COMPOSITION | Amylin Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008019143-A9 | USE OF EXENDINS AND GLP-I RECEPTOR AGONISTS FOR ALTERING LIPOPROTEIN PARTICLE SIZE AND SUBCLASS COMPOSITION | AMYLIN PHARMACEUTICALS INC (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008019143-A2 | USE OF EXENDINS AND GLP-I RECEPTOR AGONISTS FOR ALTERING LIPOPROTEIN PARTICLE SIZE AND SUBCLASS COMPOSITION | AMYLIN PHARMACEUTICALS, INC (US) | 2008-02-14 | — | — | WO | disclosed |